Identification of Genetic Factors Predisposing to Dysglobulinemia

Who is this study for? Patients with Dysglobulinemia
What treatments are being studied? Genetic Analysis of Peripheral Blood Samples
Status: Completed
Location: See all (47) locations...
Intervention Type: Genetic
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Multiple Myeloma (MM) is a malignant proliferation of monoclonal plasma cells. Myeloma accounts for almost 14% of all hematologic cancers and is essentially incurable. Myeloma commonly evolves from a precursor disease, Monoclonal gammopathy of undetermined significance (MGUS). Despite intensive study, the etiology of MGUS and myeloma are unknown and no lifestyle or environmental exposure factors have been identified that are consistently linked to increased risk of MM, MGUS or the transition between the two. The overall goal is to identify risk genes for dysglobulinemia, and more specifically Multiple Myeloma. This will involve the conservation of cells in a bank and genetic sequencing on samples obtained from families with at least two cases of dysglobulinemia. Material used for sequencing is likely to include fresh peripheral blood cells or lymphoblastoid lines established from peripheral blood lymphocytes of patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• 2 cases per family at least

• 1 case alive at least

• biological material available for 1 case at least

• Patients give their informed consent

• attached to the French Health protection service

Locations
Other Locations
France
CHU d'ABBEVILLE
Abbeville
CHU Amiens Picardie
Amiens
CHU Groupe Hospitalier Sud Hématologie Clinique
Amiens
CH d'Avignon
Avignon
CHU de Besançon
Besançon
CH de Blois Service d'Hématologie
Blois
Hôpital Avicenne Service d'Hématologie
Bobigny
Service d'Hématologie clinique et Thérapie Cellulaire, CHU de BORDEAUX
Bordeaux
CHU Morvan
Brest
Service d'hématologie Clinique
Caen
Hématolgie- Hôpital privé Cesson-Sévigné
Cesson-sévigné
CH William Morey, Service d'Hémato-Oncologie
Chalon-sur-saône
CHU de Chartres
Chartres
Département d'Oncogénitique - Centre Jean Perrin
Clermont-ferrand
Hôpital Sud Francilien
Corbeil-essonnes
Service d'Hématologie Clinique, CHU de Dijon
Dijon
Centre Hospitalier de Dunkerque
Dunkerque
Service de Médecine Interne-Hématologie, CHU de Fort de France Fort de France
Fort-de-france
CHU Albert Michallon
Grenoble
GHM, Institut Daniel Hollard
Grenoble
Service d'Hématologie, CHU de Versailles
Le Chesnay
Centre Jean Bernard Clinique Victor Hugo
Le Mans
Service d'Onco-hématologie, Hôpital Saint-Vincent GH-ICL
Lille
Service des Maladies du Sang CHU Lille
Lille
Département d'Oncogénétique, Centre Paoli Calmettes
Marseille
CHR-Metz-Thionville, Hôpital de Mercy, Service d'Hématologie
Metz
CHU d'Annecy
Metz-tessy
Hôpital Saint-Eloi, Département d'Hématologie clinique
Montpellier
Service d'Oncologie Médical, Centre Azuréen de Canrérologie-1
Mougins
CHU-HÔTEL -Dieu de Nantes
Nantes
Hôpital de l'Archet 1
Nice
CHU Carémeau
Nîmes
Hôpital St Antoine Service des maladies du Sang
Paris
Institut Curie
Paris
Jean Paul FermandService Immuno-Hématologie Hôpital Saint Louis
Paris
Hospices Civils de Lyon
Pierre Benite
Service d'Oncologie-Radiothérapie - CHU Pointe-à-Pitre/Abymes Guadeloupe
Pointe-à-pitre
CHU de Poitiers
Poitiers
Hôpital Robert Debré Service du Professeur A. DELMER Hématologie Clinique
Reims
CHU de Rennes Hôpital Sud
Rennes
CH de Rodez
Rodez
Hôpital de Saint- Germain en Laye
Saint-germain-en-laye
Département d'Hématologie à l'Institut de Cancérologie de la Loire
Saint-priest-en-jarez
Hôpital Purpan Service d'Hématologie
Toulouse
Centre Hospitalier de Valence
Valence
CHU de Nancy, Hôpital de Brabois
Vandœuvre-lès-nancy
Hôpital Privé de Villeneuve d'Ascq
Villeneuve D'ascq
Time Frame
Start Date: 2008-02-06
Completion Date: 2023-09-25
Participants
Target number of participants: 1868
Treatments
Experimental: Identification of genetic factors in dysglobulinemia cases
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov